Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma,...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of DRTS is 8.9 and suggests 24% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell